SYVN1 Promotes STAT3 Protein Ubiquitination and Exerts Antiangiogenesis Effects in Retinopathy of Prematurity Development
Investigative Opthalmology & Visual Science · 2023
DOI: 10.1167/iovs.64.11.8 ↗At a glance
Journal article in Investigative Opthalmology & Visual Science, 2023. Written by Shimei Chen and 13 co-authors. Institution: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Ocular Fundus Di…. Major MEDLINE topics: Retinopathy of Prematurity, Retinal Neovascularization. Cited 14 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
SYVN1, a gene involved in endoplasmic reticulum-associated degradation, has been found to exert a protective effect by inhibiting inflammation in retinopathy. This study aimed to clarify whether SYVN1 is involved in the pathogenesis of retinopathy of prematurity (ROP) and its potential as a candidate for target therapy.
Methods
Human retinal microvascular endothelial cells (hRMECs) and a mouse model of oxygen-induced retinopathy (OIR) were used to reveal the retinopathy development-associated protein expression and molecular mechanism. An adenovirus overexpressing SYVN1 or vehicle control was injected intravitreally at postnatal day 12 (P12), and the neovascular lesions were evaluated in retinal flatmounts with immunofluorescence staining, and hematoxylin and eosin staining at P17. Visual function was assessed by using electroretinogram (ERG).
Results
Endogenous SYVN1 expression dramatically decreased in hRMECs under hypoxia and in ROP mouse retinas. SYVN1 regulated the signal transducer and activator of transcription 3 (STAT3)/vascular endothelial growth factor (VEGF) axis. SYVN1 overexpression promoted ubiquitination and degradation of STAT3, decreased the levels of phospho-STAT3, secretion of VEGF, and formation of neovascularization in hRMECs, which could be rescued by STAT3 activator treatment. In addition, SYVN1 overexpression prevented neovascularization and extended physiologic retinal vascular development in the retinal tissues of OIR mice without affecting retinal function.
Conclusions
SYVN1 has a protective effect against OIR, and the molecular mechanisms are partly through SYVN1-mediated ubiquitination of STAT3 and the subsequent downregulation of VEGF. These findings strongly support our assumption that SYVN1 confers ROP resistance and may be a potentially novel pharmaceutical target against proliferative retinopathy.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedici…
- Department of Ophthalmology, Shanghai Aier Eye Hospital, Xuhui District, Shanghai Aier Eye Institute, Shanghai, China.
Cite
APA
Chen, S., Zhang, J., Sun, D., Wu, Y., Fang, J., Wan, X., Li, S., Zhang, S., Gu, Q., Shao, Q., Dong, J., Xu, X., Wei, F., & Sun, Q. (2023). SYVN1 Promotes STAT3 Protein Ubiquitination and Exerts Antiangiogenesis Effects in Retinopathy of Prematurity Development. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.64.11.8
Vancouver
Chen S, Zhang J, Sun D, Wu Y, Fang J, Wan X, et al. SYVN1 Promotes STAT3 Protein Ubiquitination and Exerts Antiangiogenesis Effects in Retinopathy of Prematurity Development. Investigative Opthalmology & Visual Science. 2023. doi:10.1167/iovs.64.11.8
BibTeX
@article{Chen2023,
author = {Chen, Shimei and Zhang, Jian and Sun, Dandan and Wu, Yidong and Fang, Junwei and Wan, Xiaoling and Li, Shenping and Zhang, Shuchang and Gu, Qing and Shao, Qing and Dong, Jun and Xu, Xun and Wei, Fang and Sun, Qiao},
title = {SYVN1 Promotes STAT3 Protein Ubiquitination and Exerts Antiangiogenesis Effects in Retinopathy of Prematurity Development},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
doi = {10.1167/iovs.64.11.8}
}
EUVIMED